MedTrace Logo

A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)

NCT03785366 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2025-08-15

Study results available
· View outcomes & findings →

Summary

to Assess the Pharmacokinetic Properties of VeraCept® Intrauterine Contraceptive vs ParaGard® in Healthy, Post- Menarcheal Women

Conditions

  • Women at Risk for Pregnancy

Interventions

DRUG

VeraCept

VeraCept Intrauterine Device (IUD)

DRUG

ParaGard

ParaGard intrauterine copper contraceptive

Sponsors & Collaborators

  • Synteract, Inc.

    collaborator INDUSTRY

  • Sebela Women's Health Inc.

    lead INDUSTRY

Principal Investigators

  • David Turok, MD, MPH · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-17
Primary Completion
2019-12-30
Completion
2024-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03785366 on ClinicalTrials.gov